JAGX (Jaguar Health) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAGX Jaguar Health Inc JAGX
38 GF Score
Price $0.79
GF Value $119.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Jaguar Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Jaguar Health Valuation Rank Related Terms

JAGX
38GF Score
Jaguar Health Inc JAGX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jaguar Health (JAGX) Overvalued in 2026?

Based on GuruFocus' analysis, Jaguar Health stock appears to be undervalued. The current stock price of $0.79 is trading 99.3% below its estimated GF Value™ of $119.37. GuruFocus considers Jaguar Health to be Possible Value Trap.

Key valuation signals for JAGX:

  • Valuation Rank:
  • GF Value™: $119.37 vs. price of $0.79 (99.3% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the JAGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jaguar Health Business Description

Address 200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
38GF Score

Get the complete analysis for JAGX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price
$119.37
GF Value